<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549185</url>
  </required_header>
  <id_info>
    <org_study_id>TED6828</org_study_id>
    <nct_id>NCT00549185</nct_id>
    <nct_alias>NCT00539682</nct_alias>
  </id_info>
  <brief_title>Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma</brief_title>
  <official_title>An Open-label Multi-dose-escalation, Safety and Pharmacokinetic Study of SAR3419 Administered as a Single Agent by Intravenous Infusion Every 3 Weeks in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine the maximum tolerated dose of SAR3419 and to
      characterize the dose limiting toxicity(ies). Secondary objectives are to determine the
      anti-lymphoma activity, the global safety and the PK profile.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicity(ies) at each tested dose level</measure>
    <time_frame>Study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response (complete response, partial response, stable disease) according to Cheson criteria and duration of response</measure>
    <time_frame>Study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Study period</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">39</enrollment>
  <condition>Lymphoma</condition>
  <condition>Non-Hodgkin</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR3419</intervention_name>
    <description>Intravenous infusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed CD19-positive non-Hodgkin's B-cell lymphoma, relapsed or
             refractory after standard treatments, with no curative option with conventional
             therapy

          -  ECOG performance status 0 to 2

        Exclusion Criteria:

          -  Burkitt's lymphoma, Lymphoblastic lymphoma, Chronic lymphocytic leukemia (Small
             lymphocytic lymphoma may be included)

          -  Chemotherapy or radiation therapy or other investigational agents within 4 weeks prior
             to entering the study

          -  Previous radioimmunotherapy within 12 weeks

          -  Known intolerance to infused protein products or maytansinoids

          -  Poor kidney, liver and bone marrow functions

          -  Any serious active disease or co-morbid condition, which in the opinion of the
             principle investigator, will interfere with the safety or with compliance with the
             study

          -  Pregnant or breast-feeding women

          -  Patient with reproductive potential without effective birth control methods

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2007</study_first_submitted>
  <study_first_submitted_qc>October 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2007</study_first_posted>
  <last_update_submitted>February 13, 2012</last_update_submitted>
  <last_update_submitted_qc>February 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

